Table 4 Tactic table for the indifferent drug regulators
Expected outcome: Approval for the conduct of the chemoPAD study and use of study results to guide the registration of chemotherapy drugs in the country | |
|---|---|
Major current issue occupying stakeholder attention: The regulatory authority does not have the tools and capabilities to screen for the quality of anticancer drugs before authorizing their use in the market or tools to check for the circulation of SF drugs in the market | |
Tactic | Response |
Deploy capabilities to solve indifferent problems in order to their secure support | • Train regulators on screening for the quality of anticancer drugs • Arranged for the laboratory arm of the regulatory agency to go for an exchange visit to a drug testing laboratory in the USA for capacity building |
Deploy resources to galvanize support from indifferent | • The study team does not have such resources |
Leverage allies or ally’s allies in our network to mobilize indifferents | • Organize a meeting between the lead oncologist and regulators so that the oncologist can share their experiences with the regulators |